DOCSLIB.ORG

E-Update Tracy J

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
E-Update Tracy J John R. Kasich, Governor e-Update Tracy J. Plouck, Director Recovery Promoting Wellness and July 2016 Naloxone Grant Program Results in SFY 2016 Overdose Reversals 2,300 Overdose Reversals in SFY 2016 As reported by county health departments State efforts to make the lifesaving over- Funds were allocated on LAKE ASHTABULA LUCAS WILLIAMS FULTON 15 dose reversal medication naloxone more a per capita basis, with a 78 OTTAWA GEAUGA CUYAHOGA HENRY WOOD ERIE LORAIN accessible to communities throughout Ohio minimum of $1,800 guar- DEFIANCE SANDUSKY 2 83 TRUMBULL 35 62 are showing positive results. According to anteed to each county. SUMMIT P0RTAGE SENECA HURON 22 PAULDING MEDINA 6 PUTNAM HANCOCK 2 MAHONING new data gathered by the Ohio Department According to data 5 ASHLAND WYANDOT CRAWFORD 2 VAN WERT WAYNE of Mental Health and Addiction Services collected by OhioMHAS COLUMBIANA ALLEN 12 RICHLAND STARK 8 HARDIN (OhioMHAS) Office of Quality, Planning research staff, 78 county MARION 17 AUGLAIZE HOLMES CARROLL MERCER 3 47 MORROW and Research, more than 7,800 naloxone public health boards K NOX JEFFERSON LOGAN TUSCARAWAS SHELBY UNION COSHOCTON kits/units were purchased through a grant signed up to participate 4 8 DELAWARE HARRISON CHAMPAIGN 5 1 DARKE program established in the last budget, in the initiative during SFY LICKING MIAMI GUERNSEY BELMONT FRANKLIN MUSKINGUM resulting in 2,363 lives saved. 2016. Of the 10 coun- CLARK 239 2 MONTGOMERY 21 PREBLE MADISON FAIRFIELD NOBLE MONROE The Kasich Administration’s latest bien- ties that did not utilize PERRY GREENE 134 PICKAWAY 1 MORGAN nial budget included $1 million ($500,000 any of the funds, only 6 FAYETTE 5 HOCKING WARREN 4 5 per year) to provide naloxone to all 88 three did not establish BUTLER CLINTON WASHINGTON ROSS 240 9 ATHENS 2 VINTON counties through grants to local health an account with the Ohio HAMILTON HIGHLAND 61 1,159 MEIGS CLER- PIKE 2 authorities. The funds, which were allocated Pharmacy Service Center MONT JACKSON BROWN GALLIA 15 ADAMS to OhioMHAS, were used to purchase nal- — Lawrence, Monroe and SCIOTO 6 oxone, including complete Project DAWN Perry. As of July, Lawrence 35 LAWRENCE (Deaths Avoided With Naloxone) kits, for County had established distribution to county health departments an account and has begun TOTAL REVERSALS STATEWIDE: 2,363 to dispense to local law enforcement, emer- to order kits with Year Two Source: OhioMHAS, Office of Quality Planning and Research gency personnel and first responders. funding. Be the 95% Campaign Sweeps National Awards OhioMHAS SFY 2016 Annual The Ohio for Responsible Gambling (ORG) “Be the 95%” Problem Gambling Prevention Report Available Online Campaign won four national awards at the National Council on Problem Gambling The State Fiscal Year 2016 Annual Report is conference in New York in July. Accepting the awards from Ohio were the ORG partners, now available for viewing on our website representatives from Drug Free Action Alliance (DFAA), who manage the grant for the and it includes hyperlinks to more infor- campaign, and Origo Branding, the campaign’s creative agency. mation on many Pictured L-R: Krysta Bennett topics. The report (DFAA), Scott Anderson (Ohio salutes all of the Department of Mental Health partners in both the and Addiction Services- public and private OhioMHAS), Tristan Hall sectors that help us (DFAA), Shemane Marsh advance our mis- (OhioMHAS), Alessandro sion and make Ohio Ciaffoncini (Origo), Stacey stronger. New ini- Frohnapfel-Hasson tiatives, along with (OhioMHAS) and Karen Russo the continued core (Ohio Lottery Commission). investments in prevention, treatment and The campaign won awards recovery services, are making a difference for Public Awareness, Social for Ohioans with substance abuse, gam- Media, Website and Best in bling addiction and mental health needs Prevention Showcase. to support safe and healthy communities. mha.ohio.gov Find us on: OhioMHAS e-Update July 2016 2 Northwest Ohio Psychiatric Hospital On the Road Names New Chief Clinical Officer Dr. Robert Karp has been appointed Chief Clinical with Director Plouck Officer at the Nortwhest Ohio Psychiatric Hospital in Toledo. Dr. Karp joined the NOPH clinical team in ASHTABULA LUCAS LAKE FULTON 2007. He previously served as medical director for the WILLIAMS OTTAWA GEAUGA Maumee Valley Guidance Center. WOOD CUYAHOGA HENRY SANDUSKY LORAIN TRUMBULL DEFIANCE ERIE Dr. Karp completed his residency in Psychiatry at HURON SUMMIT P0RTAGE SENECA MEDINA Northwestern University Hospital in Chicago and is a PAULDING HANCOCK MAHONING PUTNAM ASHLAND Life Fellow of the American VAN WERT WYANDOT CRAWFORD WAYNE COLUMBIANA Psychiatric Association and ALLEN RICHLAND STARK HARDIN MARION CARROLL member of the Royal College MERCER AUGLAIZE MORROW HOLMES K NO X of Psychiatry. LOGAN JEFFERSON TUSCARAWAS SHELBY UNION COSHOCTON Dr. Karp retired from the Air DELAWARE HARRISON DARKE CHAMPAIGN Force where he was trained as LICKING MIAMI MUSKINGUM BELMONT GUERNSEY CLARK a Flight Surgeon and served FRANKLIN PREBLE MONTGOMERY MADISON FAIRFIELD MONROE as the Medical Commander PERRY NOBLE GREENE PICKAWAY MORGAN FAYETTE of an F-16 fighter wing, and BUTLER WARREN CLINTON HOCKING WASHINGTON later, as State Air Surgeon for ROSS ATHENS VINTON Indiana. During his military HIGHLAND HAMILTON Dr. Karp MEIGS career, he attended Air War CLER- PIKE MONT JACKSON BROWN GALLIA College, the nation’s highest school for military leaders ADAMS SCIOTO and was a consultant to the Surgeon General of the Air LAWRENCE National Guard. Twin Valley Behavioral Healthcare A brief recap of Dir. Plouck’s public activities this month: Names New Chief Clinical Officer 7.7 Visited the Ohio Department of Rehabilitation and Dr. Ann Morrison has been appointed Chief Clinical Correction’s Correctional Reception Center in Orient. Officer of Twin Valley Behavioral Healthcare (TVBH). As CCO, Dr. Morrison will be responsible for leading and 7.11 Visited Neil Kennedy Recovery Center in Youngstown recruiting a diverse medical staff and oversee collab- to discuss recovery housing, behavioral health redesign orative efforts between the hospital and community and the local continuum of care. partners. She joined the TVBH clinical team as a staff psychiatrist in 2013, and 7.20 Moderated a policy panel on the opiate crisis, featuring was named Assistant Chief Sen. Rob Portman, Attorney General of Ohio Mike Clinical Officer in November DeWine and medical leaders on opioid abuse. The 2015. Prior to coming to the presentation was sponsored by the Cleveland 2016 Host hospital, Dr. Morrison served Committee and JobsOhio. as an Associate Professor and Director of Community 7.22 Attended the Summit County kickoff for the national Psychiatry at Wright State mental health “Change Direction” campaign. University. Dr. Morrison is Board 7.28 Spoke at a panel in East Liverpool about workforce Certified in General and development organized by the Ohio Chamber of Forensic Psychiatry and is Dr. Morrison Commerce. a Distinguished Fellow of the American Psychiatric Association. She completed her undergraduate work SAVE THE DATE! 2016 Ohio Rally for Recovery at Macalester College and continued her education in medicine and psychiatry at the University of Wisconsin Friday, Sept. 23 | 1-3 p.m. | Ohio Statehouse School of Medicine and Public Health. She has been recognized by the National Alliance on Mental Illness, For more information, call 614.486.2430 Dayton Police Department and the Ohio Psychiatric Physicians Association. mha.ohio.gov OhioMHAS e-Update July 2016 3 Pictured L-R: Former U.S. Speaker of the House Newt Gingrich, National Alliance on Mental Illness of Ohio Executive Director Terry Russell and the Alcohol, Drug Addiction and Mental Health Services Board of Cuyahoga County Chief Executive Officer William Denihan participate in a mental health advocacy event on July 19 as part of the Republican National Convention in Cleveland. Awareness and Advocacy Event Seeks to Bring Mental Illness Out of the Shadows As the world turned its eyes to Cleveland for the Republican “The words of the speakers were exceptionally power- National Convention, the National Alliance on Mental Illness ful, and stand as a testimony to the urgency of the need to of Ohio seized the spotlight to host a “Bringing Mental Illness reform America’s mental health system and Bring Mental Out of the Shadows” advocacy event. Illness Out of the Shadows,” said NAMI Ohio Policy Director The July 19 gathering featured remarks from a star-studded Dustin McKee. “We are proud to be the voice of individuals cast of experts and policy makers, includ- and families who are living with mental ing former U.S. Speaker of the House illness, and will continue to advocate for Newt Gingrich, Attorney General of Ohio policies that enhance their lives. We look Mike DeWine, Congressman Bill Johnson, forward to maintaining this effort for re- State Sen. Robert Hackett, State Sen. form in Congress and the Ohio General Frank LaRose and State Rep. Scott Ryan, Assembly.” NAMI Ohio Executive Director Terry Russell, Fred Frese, Ph.D., The Margaret Clark Morgan Foundation, The Woodruff and Alcohol, Drug Addiction and Mental Health Services Foundation, NAMI of Greater Cleveland, ADAMHS Board of Board Chief Executive Officer William Denihan, among oth- Cuyahoga County, Community Hospital Systems, Murtis Taylor ers. The event also included speeches from individuals living Community Mental Health Center, The Magnolia Clubhouse with mental illness and family members impacted by mental and others provided support for the event. Click HERE to view illness. video remarks from the NAMI Ohio Facebook page. Opiate Epidemic in Focus at Cleveland Policy Summit OhioMHAS Director Tracy Plouck moderated a July 20 Public and Private Solutions to America’s Opioid Crisis policy panel sponsored by the Cleveland 2016 Host Committee and JobsOhio. The panel featured remarks from Attorney General of Ohio Mike DeWine (far left), Erin Hoeflinger, president, Anthem Blue Cross/Blue Shield of Ohio, Dr. Richard Rosenquist, chairman, Cleveland Clinic, Department of Pain Management (right) and Sen.
Load more

Recommended publications
  • Decreased Dopamine Brain Reactivity in Marijuana Abusers Is Associated
    Decreased dopamine brain reactivity in marijuana PNAS PLUS abusers is associated with negative emotionality and addiction severity Nora D. Volkowa,b,1, Gene-Jack Wanga, Frank Telanga, Joanna S. Fowlerc,1, David Alexoffc, Jean Logand, Millard Jaynea, Christopher Wonga, and Dardo Tomasia aLaboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, Rockville, MD 20857; bNational Institute on Drug Abuse, Rockville, MD 20857; cBiosciences Department, Brookhaven National Laboratory, Upton, NY 11973; and dDepartment of Radiology, New York University Langone Medical Center, New York, NY 10016 Contributed by Joanna S. Fowler, June 20, 2014 (sent for review April 9, 2014; reviewed by Bertha Madras, Harvard University Medical School, and Karen Berman, National Institute of Mental Health) Moves to legalize marijuana highlight the urgency to investigate ref. 6). Similarly, cocaine abusers (17, 18) and alcoholics (19, 20), effects of chronic marijuana in the human brain. Here, we chal- but not marijuana abusers (16), show attenuated DA increases in lenged 48 participants (24 controls and 24 marijuana abusers) with striatum when challenged with a stimulant drug, although mar- methylphenidate (MP), a drug that elevates extracellular dopamine ijuana abusers with comorbid schizophrenia or risk for schizo- (DA) as a surrogate for probing the reactivity of the brain to DA phrenia showed blunted DA increases to stimulants (21) and to stimulation. We compared the subjective, cardiovascular, and brain stress (22). However, prior studies are limited by their small DA responses (measured with PET and [11C]raclopride) to MP be- sample sizes (ranging from six to 16 subjects). Also, prior studies tween controls and marijuana abusers.
    [Show full text]
  • (SBIRT) for Illicit Drug and Alcohol Use at Multiple Healthcare Sites: Comparison at Intake and 6 Months Later Bertha K
    Available online at www.sciencedirect.com Drug and Alcohol Dependence 99 (2009) 280–295 Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: Comparison at intake and 6 months later Bertha K. Madras a,∗, Wilson M. Compton b, Deepa Avula c, Tom Stegbauer c, Jack B. Stein c, H.Westley Clark c a Harvard Medical School-NEPRC, 1 Pine Hill Drive, Southborough, MA 01772, USA b Division of Epidemiology, Services and Prevention Research, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20892-9561, USA c Substance Abuse and Mental Health Services Administration, Department of Health and Human Service, 1 Choke Cherry Road, Rockville, MD 20857, USA Received 15 April 2008; received in revised form 28 August 2008; accepted 29 August 2008 Available online 16 October 2008 Abstract Objectives: Alcohol screening and brief interventions in medical settings can significantly reduce alcohol use. Corresponding data for illicit drug use is sparse. A Federally funded screening, brief interventions, referral to treatment (SBIRT) service program, the largest of its kind to date, was initiated by the Substance Abuse and Mental Health Services Administration (SAMHSA) in a wide variety of medical settings. We compared illicit drug use at intake and 6 months after drug screening and interventions were administered. Design: SBIRT services were implemented in a range of medical settings across six states. A diverse patient population (Alaska Natives, American Indians, African-Americans, Caucasians, Hispanics), was screened and offered score-based progressive levels of intervention (brief intervention, brief treatment, referral to specialty treatment).
    [Show full text]
  • Alan Macdiarmid Term Professor Kevin B
    UNIVERSITY OF PENNSYLVANIA Tuesday April 2, 2019 Volume 65 Number 29 www.upenn.edu/almanac Ivan Dmochowski: Alan MacDiarmid Term Professor Kevin B. Mahoney: Ivan Dmochowski, (C’50, HON’99) and Diana T. Vagelos, Penn Chief Executive Officer, University professor of chemis- parents, in honor of longtime Nobel Prize-win- of Pennsylvania Health System try, has been named the ning chemistry professor Dr. Alan MacDiarmid. Kevin B. Mahoney will become the next Alan MacDiarmid Term Dr. P. Roy Vagelos, a chemistry major who CEO of the University of Pennsylvania Health Professor of Chemis- graduated from Penn in 1950 before going on to System (UPHS), Uni- try. Dr. Dmochowski’s receive a medical degree from Columbia Uni- versity of Pennsyl- laboratory develops versity, is the retired chairman and chief execu- vania President Amy chemical and biophysi- tive officer of Merck & Co. He currently serves Gutmann and J. Lar- cal tools to study com- as chairman of the Board at Regeneron Pharma- ry Jameson, executive plex biological systems, ceuticals. Dr. Vagelos served as chair of the Uni- vice president of the including new tech- versity’s Board of Trustees from 1995 to 1999, University of Pennsyl- nologies for biomolec- and he is a former member of the Penn Arts and vania for the Health Ivan Dmochowski ular imaging, identify- Sciences’ Board of Overseers and the former System and dean of ing proteins and RNA molecules important in chair of the Committee for Undergraduate Fi- the Perelman School of brain function, and fabricating functional bio- nancial Aid. Diana T. Vagelos is a former over- Medicine, announced.
    [Show full text]
  • Adoption of NIDA's Evidence-Based
    2012 Adoption of NIDA’s Evidence-Based Treatments in Real World Settings ---A National Advisory Council on Drug Abuse Workgroup Report This report is produced in response to a charge by the NIDA Director for the Workgroup to: 1) Determine how effectively the treatment interventions developed, tested, and evaluated through NIDA’s extramural programs are being transferred and utilized in real world settings (e.g. community treatment centers, primary care settings, criminal justice settings, etc.); 2) Explore barriers for moving from research findings to adoption as standard practice; and 3) Consider whether and how the organization of NIDA could be best structured to meet these evolving scientific goals. National Advisory Council on Drug Abuse National Institute on Drug Abuse i September 6, 2012 ~ UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM Abramson Cancer Center Department of PS)l chiatr~' Anncnbcrg Public Policy Center Caryn Lerman. Ph.D . .."f ar.\' W Ca/kills Pro/l's.WJr lJ epllly /);1'('('(01: Abramso" Callcer Celllt'" July 30, 2012 Nora D. Volkow, M.D., Director National Institute on Drug Abuse 6001 Executive Boulevard Bethesda, MD 20892 Dear Dr. Volkow: I am pleased to transmit the report and recommendations of the National Advisory Council on Drug Abuse Work Group "Adoption 0/ NJDA 's Evidence Based Treatments in Real World Sellings". This Work Group was created at your request in 2011. The report and recommendations reflect the unanimous view of the Work Group members. We take full responsibility for the contents and are available to meet with you and/or members of your staff to discuss our conclusions and recommendations, if needed.
    [Show full text]
  • Commission on Combating Drug Addiction and the Opioid Crisis
    THE PRESIDENT’S COMMISSION ON COMBATING DRUG ADDICTION AND THE OPIOID CRISIS Roster of Commissioners Governor Chris Christie, Chairman Governor Charlie Baker Governor Roy Cooper Congressman Patrick J. Kennedy Professor Bertha Madras, Ph.D. Florida Attorney General Pam Bondi Table of Contents Chairman’s Letter…………………………………………………………………………………5 Summary of Recommendations .................................................................................................... 12 The Drug Addiction and Opioid Crisis ......................................................................................... 19 Origins of the Current Crisis ..................................................................................................... 19 Magnitude and Demographics .................................................................................................. 23 Newly Emerging Threats .......................................................................................................... 26 Pathways to Opioid Use Disorder (Including Heroin) from Prescription Opioids ................... 27 Health, Financial, and Social Consequences ............................................................................. 29 Drug Overdose Deaths .............................................................................................................. 31 Substance Use Treatment Availability ...................................................................................... 32 Systems Approach to Solutions ...............................................................................................
    [Show full text]
  • Leadership Conference on Medical Education in Substance Abuse
    OFFICE OF NATIONAL DRUG CONTROL POLICY Leadership Conference on Medical Education in Substance Abuse “Let us bring to all Americans who struggle with…addiction this message of hope: The miracle of recovery is possible, and it could be you.” President George W. Bush, State of the Union Address, January 20, 2003 Washington, DC December 1-2, 2004 CONFERENCE AGENDA OFFICE OF NATIONAL DRUG CONTROL POLICY LEADERSHIP CONFERENCE ON MEDICAL EDUCATION IN SUBSTANCE ABUSE Washington, DC, December 1-2, 2004 WEDNESDAY, DECEMBER 1, 2004 THURSDAY, DECEMBER 2, 2004 continued 6:00 - 9:00 PM 9:20 - 9:40 am Health Professions Education: 5:00 pm Registration opens (Hotel Mezzanine) The View from NIAAA Ting-Kai Li, M.D. 6:00 pm Dinner Meeting (Consulate Room, Director, National Institute on Mezzanine Level) Alcohol Abuse and Alcoholism 6:00 - 6:10 pm Welcome and Acknowledgments 9:40 - 10:00 am Questions and Discussion Addison D. “Tad” Davis IV (Dr. Volkow & Dr. Li) Acting Deputy Director for Demand Reduction Office of National Drug 10:00 - 10:10 am Overview of the Day and Introduction Control Policy of the Small Group Chairs Mr. Davis & Mrs. Wilford 6:10 - 7:00 pm Dinner (generously sponsored by The Robert Wood Johnson Foundation) 10:15 - 10:30 am Break 7:00 - 7:10 pm Introduction of the Panelists (Mr. Davis) 10:30 - 12:00 pm Small Groups Meet — Session 1 Group 1 (Undergraduate Medical Education) 7:10 - 8:00 pm Panel Discussion Dr. Bertha K. Madras, Group 2 (Graduate Medical Education) Dr. Sheldon Miller, Dr. Mark L. Kraus Group 3 (Continuing Medical Education) 8:00 - 8:30 pm Questions and Discussion 12:00 - 12:50 pm Working Lunch 8:30 - 9:00 pm Overview of Thursday’s Activities and 12:50 - 1:10 pm Health Professions Education: Adjourn for the Evening The View from NHTSA Mr.
    [Show full text]
  • The American Opioid Epidemic in Special Populations: Five Examples
    DISCUSSION PAPER The American Opioid Epidemic in Special Populations: Five Examples Carlos Blanco, MD, PhD, National Institute on Drug Abuse; Mir M. Ali, PhD, Offi ce of the Assistant Secretary of Planning and Evaluation; Aaron Beswick, MSW, MPH, Health Resources and Services Administration, Federal Offi ce of Rural Health Policy; Karen Drexler, MD, Veterans Aff airs Administration; Cheri Hoff man, Offi ce of the Assistant Secretary for Planning and Evaluation; Christopher M. Jones, PharmD, DrPH, Centers for Disease Control and Prevention; Tisha R. A. Wiley, PhD, National Institute on Drug Abuse; Allan Coukell BSc(Pharmacy), Civica Inc.; and the Prevention, Treatment, and Recovery Working Group of the Action Collaborative on Countering the U.S. Opioid Epidemic October 26, 2020 Disclaimer: The views expressed in this paper are those of the authors and not necessarily of the authors’ organizations, the National Academy of Medicine (NAM), or the National Academies of Sciences, Engineering, and Medicine (the National Academies). This paper is intended to inform and stimulate discussion. It is not a report of the NAM or the National Academies. The United States is in the midst of an unprecedented proaches in supporting this population, and high-im- crisis of prescription and illicit opioid misuse, use dis- pact research and action priorities. order, and overdose. In 2018, nearly 47,000 Americans died from an overdose involving opioids [174]. In 2018, Justice-Involved Populations 10.3 million people aged 12 years and older reported misusing prescription opioids or using heroin, and 2 The Importance of Justice-Involved Populations million met the diagnostic criteria for having an opi- Economic decline, incarceration, and drug-related oid use disorder in the past year—lower than 2015 mortality are tightly connected at a population level through 2017 [150].
    [Show full text]
  • Download the Transcript
    2017-10-05-dea_0 Female: 2017, 2018 program. This year's overarching topic is A New Look at Some Old and Not So Old Drugs, future programs will focus on cocaine, opioids and heroin and mood synthesizers, synthetic drugs. Not only do we have people in the audience here at DEA Headquarters in Washington DC but there are folks watching through a live webcast around the country and we hope around the world if people want to get up in the middle of the night to watch this. Dr. Mark Gold [PH] who put this panel together for us is watching from Yale and we thank Dr. Gold very much for his work on bringing these esteemed people to our stage today. I particularly want to welcome the Texas Museum of Science and Technology in Cedar Park, Tex MOST is hosting [00:01:00] our traveling exhibition drugs cause and consequences and their staff jumped at the chance to simulcast this program at their museum today. A pleasant reminder, turn off your cell phones please. With marijuana in the news both with state level legalization efforts and research on its effects on the body and brain, we have four renowned international researchers providing updates on these issues. Our moderator today is Robert L. DuPont a national leader in marijuana policy, drug policy and treatment, he was the first director of the National Institute on Drug Abuse from 1973 to 1978 and was the second White House Drug Czar from 1973 to 1977. In 1978 Dr. DuPont became the founding president of the Institute for Behavior and Health and in 1982 he and former DEA Administrator [00:02:00] Peter Bensinger founded Bensinger DuPont & Associates a national consulting firm.
    [Show full text]
  • ACNP 59Th Annual Meeting: Panels, Mini-Panels and Study Groups
    www.nature.com/npp ABSTRACTS COLLECTION ACNP 59th annual meeting: panels, mini-panels and study groups Neuropsychopharmacology (2020) 45:1–67; https://doi.org/10.1038/s41386-020-00889-0 Sponsorship Statement: Publication of this supplement is sponsored by the ACNP. Individual contributor disclosures may be found within the abstracts. Asterisks in the author lists indicate presenter of the abstract at the annual meeting Study Group programs at UCLA and nationally. Dr. Shawn McClintock will present on how inclusion and diversity can be infused into the 1. Inclusion and Diversity Efforts Within Large Scientific continuing education and scientific programs as part of the ACNP Organizations: Tangible Methods: That Work conference, as well as strategies to translate knowledge from the conference to the membership’s place of work. Dr. Sade Spencer April Thames*, Sade Spencer, Lisa Eyler, Shawn McClintock, (co-Chair) will lead an interactive discussion and exercise to Erika Nurmi engage the audience in determining an action intention to take 1234567890();,: back with them to their spheres of influence based on what they Study Group Summary: Owing to the scarcity of women and have learned in the symposium. Overall, this timely and innovative underrepresented minorities in science especially in senior and work group sets the stage within and beyond the ACNP leadership roles, diversity and inclusion are aspirational “buzz- conference to ensure successful integration, implementation, words” that are used widely across institutions, organizational and long-lasting state-of-the-art diversity and inclusion practices. settings, and the scientific community. At federal, state and Disclosure: Nothing to disclose. private sector levels, billions of dollars have been allocated to “fix” this longstanding systemic problem.
    [Show full text]
  • DOC-5-BERTHA MADRAS.Ppt-Usa
    INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D Secretariat for Multidimensional Security DRUGS SUMMIT EUROPEAN, LATIN AMERICAN AND OEA/Ser.L/XIV.4.1 CARIBBEAN MAYORS AND CITIES CICAD/DREU-LAC/doc.5/10 April 21 –23, 2010 5 May2010 Lugo, Spain Original: English INTERVENTION Bertha Madras, PhD Professor Psychobiology, School of Medicine Harvard University Drug Policy, Public Health andScience Bertha K. Madras, PhD (the Honorable) Professor of Psychobiology Department of Psychiatry Harvard Medical School [Former Deputy Director for Demand Reduction White House Office of National Drug Control Policy] Ref: Uhl and Grow, 2004 Drug use: shaped by culture, access, economics, perception, information Drug Policy Goals: Limit, reduce drug use, and associated consequences to individuals, society Policy Drivers: Society, public health, law, values, economics, but based on statistics, science Successful Policy: Uses statistics, articulates goals, quantifiable outcomes, measures, accountability, flexibility • Why do people take drugs? • How drugs affect the brain? • Adaptation, addiction? • Public policy from modern biology To have novel • feelings •sensations •experiences AND To share them To alleviate anxiety worries fears Self-medication hypothesis To alleviate sadness depression hopelessness Self-medication hypothesis UUserser Drug Environment Psychiatric symptoms Prior experience with drugs Trauma Risk-seeking behavior Genetic factors Poor school achievement Age and age of onset Embedded in volitional choices are involuntary components •
    [Show full text]
  • Declaration of Bertha Madras, Ph.D
    Case 2:11-cr-00449-KJM Document 324 Filed 07/29/14 Page 1 of 36 1 BENJAMIN B. WAGNER United States Attorney 2 RICHARD BENDER SAMUEL WONG 3 GREGORY T. BRODERICK Assistant United States Attorneys 4 501 I Street, Suite 10-100 Sacramento, CA 95814 5 Telephone: (916) 554-2991 Facsimile: (916) 554-2900 6 Attorneys for Plaintiff 7 United States of America 8 IN THE UNITED STATES DISTRICT COURT 9 EASTERN DISTRICT OF CALIFORNIA 10 UNITED STATES OF AMERICA CASE NO. 2:11-CR-00449-KJM-16 11 Plaintiff, DECLARATION OF BERTHA 12 MADRAS, PH.D v. 13 BRIAN SCHWEDER, et. al. 14 Defendant, 15 16 I, Bertha K. Madras, Ph.D, declare as follows: 17 1. I am a Professor of Psychobiology at Harvard Medical School, Department of 18 Psychiatry. My office is located in the Alcohol and Drug Abuse Program at McLean Hospital, an 19 affiliate hospital of Harvard. I have been retained to offer opinions in United States v. Schweder, et. al., 20 Case No. 2:11-CR-0449-KJM (E.D. Cal.). I am not employed by the Department of Justice, the Drug 21 Enforcement Administration (DEA), or any other federal office or agency. I neither speak for, nor set 22 policy for, these agencies. Nor can I speculate about, or predict the outcome of, the rescheduling 23 petition currently pending before DEA. Rather, my opinions are my own, are based in science, and 24 reflect my 50 years of education, research, and experience in the relevant area. 25 I. SUMMARY OF QUALIFICATIONS 26 2.
    [Show full text]
  • South Florida Drug Use Trends
    SOUTH FLORIDA HIDTA Drug Use Trends OVERVIEW • Drug use trends in the SFLHIDTA • Primary and Secondary Drug Threats • Data Analysis • Drugs Identified in Deceased Persons – Florida Medical Examiners Commission • Florida Department of Children and Families – Treatment Episode Data • Florida Department of Health – EMSTARS database SOUTH FLORIDA HIDTA The SFLHIDTA represents 31 percent of the 21,477,737 residents in the State of Florida, with Miami-Dade County accounting for 40 percent of the region. Population - SFLHIDTA Region US Census Bureau Population Estimates 2019 Miami-Dade 2,716,940 Broward 1,952,778 Palm Beach 1,496,770 Collier 384,902 Martin 161,000 Monroe 74,228 Total 6,786,618 COCAINE Increased cocaine use with opioids, dubbed the “fourth wave” of the national opioid epidemic, is supported by historically high poly- drug substance abuse trends involving the deliberate or unwitting use of cocaine and/or methamphetamine with heroin and/or fentanyl. ANNUAL COCAINE DETECTED DEATHS o Increased from a historic low of 431 in 2011 to a record high 1,244 in CY 2016, with a decrease to 1,011 in CY 2018. o Interim data for the first six months of 2019 compared with the first six months of 2018 shows a slight increase from 510 in 2018 to 521 in 2019. o Although cocaine deaths stabilized in 2017, they remain at extraordinarily high levels. o Thirty-five to fifty year-olds represent 37 percent of the 1,011 cocaine deaths, with 36 percent of them attributed to Miami-Dade County, followed by Palm Beach County, with 32 percent, according to the ME report for 2018.
    [Show full text]